NCT06870110 Brain Training for Substance Use Disorders
| NCT ID | NCT06870110 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Neurotype Inc. |
| Condition | Opioid Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-01-17 |
| Primary Completion | 2025-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-01-17 with a primary completion date of 2025-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Participants play games designed to train visual attention towards natural, non-drug-related scenarios. A biofeedback loop between gameplay and an electroencephalogram (EEG) system monitors game performance and guides game difficulty.
Eligibility Criteria
Inclusion Criteria: OUD patient participants: * Admitted into chemical treatment with opioid use being a reason for treatment; * DSM-IV-TR diagnosis of OUD; * Ability to provide informed consent; * A minimum of a 6th grade reading level; and * Able and willing to provide own contact information for follow-up visit(s). Control participants: * Age- and gender-matched to an OUD patient participant in the study; * Ability to provide informed consent; * A minimum of a 6th grade reading level; * Able and willing to provide own contact information for follow-up visit(s). Exclusion Criteria: OUD patient participants: * Refusal or inability to consent; * Pregnant; * History of serious neurological illness (e.g., Chronic seizure disorder, Wernicke-Korsakoff Syndrome, Epilepsy, Any history of seizures not caused by withdrawal from substances, Other \[please specify\]); * Inability to see text and photos clearly on the computer display; and * Unwillingness to change hairstyle (e.g., braids, pony tails, dreadlocks) or remove wig to accommodate application of the EEG headset, if necessary. Control participants: * Refusal or inability to consent; * Pregnant; * History of serious neurological illness (e.g., Chronic seizure disorder, Wernicke-Korsakoff Syndrome, Epilepsy, Any history of seizures, Other \[please specify\]); * Inability to see text and photos clearly on the computer display; * Current or previous problems using opioids, other prescription (prescribed or not prescribed) or illicit drugs; * Regular nicotine user (e.g., cigarette smoker, e-cig user) within the past 12 months; and * Unwillingness to change hairstyle (e.g., braids, pony tails, dreadlocks) or remove wig to accommodate application of the EEG headset, if necessary.
Contact & Investigator
Justin Anker, PhD
PRINCIPAL INVESTIGATOR
University of Minnesota
Frequently Asked Questions
Who can join the NCT06870110 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Opioid Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06870110 currently recruiting?
Yes, NCT06870110 is actively recruiting participants. Contact the research team at burwell@umn.edu for enrollment information.
Where is the NCT06870110 trial being conducted?
This trial is being conducted at Minneapolis, United States.
Who is sponsoring the NCT06870110 clinical trial?
NCT06870110 is sponsored by Neurotype Inc.. The principal investigator is Justin Anker, PhD at University of Minnesota. The trial plans to enroll 40 participants.